Complete Story
 

04/04/2022

Priority Health Update

Priority Health Managed Care Committee Member

Flora Varga

Flora Varga, Cancer & Hematology Centers of West Michigan



Retacrit supply shortage expected soon

Pfizer informed Priority Health that Retacrit will experience a supply disruption beginning in late May 2022, with a targeted return to supply in early Q4 2022.  To see the list of covered alternatives READ MORE



Some Site of Service Restrictions Started April 1st!

Infliximab -The prior authorization requirement for Infliximab products was removed in May 2020 to remove administrative burden. Beginning April 1st, prior authorization is required for the continued administration of infliximab products at a non-preferred site of care. However, if a preferred site of care is utilized, according to the members plan, no authorization will be required.

To review other infusion therapies with site of service restrictions, CLICK HERE



 

Printer-Friendly Version